Emerging therapies for treatment of multiple sclerosis

Journal of Inflammation Research

Volumn 3, Issue 1, 2010, Pages 53-59

  Corboy, John R ^a   Miravalle, Augusto A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Immune sequestration; Lymphocyte targeted therapy; Multiple sclerosis; Non specific immune modulation

Indexed keywords

ALEMTUZUMAB; ATACICEPT; BETA INTERFERON; BETA1A INTERFERON; BG 00012; CLADRIBINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; DACLIZUMAB; FINGOLIMOD; FIRATEGRAST; GLATIRAMER; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 23; LAQUINIMOD; MYELIN BASIC PROTEIN[82-98]; NOGO A ANTIBODY; OCRELIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; UNCLASSIFIED DRUG; USTEKINUMAB;

ABDOMINAL PAIN; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BASAL CELL CARCINOMA; BLURRED VISION; BRADYCARDIA; BUDD CHIARI SYNDROME; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENCEPHALITIS; GRAVES DISEASE; HEART INFARCTION; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPERTHYROIDISM; IMMUNE DEFICIENCY; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATION; LIMB PAIN; LIVER FUNCTION TEST; LIVER NECROSIS; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; PANCYTOPENIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REMYELINIZATION; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SPINAL CORD INJURY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TH2 CELL; TH3 CELL; THORAX PAIN; THROMBOCYTOPENIC PURPURA; THYROID DISEASE; URINARY TRACT INFECTION;

EID: 77955523772     PISSN: None     EISSN: 11787031     Source Type: Book Series    
DOI: 10.2147/jir.s6558     Document Type: Article

References (43)

1. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985; 75(2):37-83.
2. Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: Not just another purine analogue? Expert Opin Investig Drugs. 2009;18(8): 1169-1181.
3. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996;93(4):1716-1720.
4. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54(5):1145-1155.
5. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999;111(1):35-44.
6. Serono E. CLARITY: A Phase III, randomized, double-blind, threearm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis. NCT00213135.
7. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17): 1786-1801.
8. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688.
9. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-471.
10. Genentech HLR. Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with RRMS. NCT00676715.
11. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103(15):5941-5946.
12. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A. 2004;101(23):8705-8708.
13. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009;66(4):483-489.
14. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial. Neurology. 2008;71(12):917-924.
15. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71(16):1261-1267.
16. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158(5):1173-1182.
17. TRANSFORMS FTY720. A 12-month study comparing the efficacy and safety of two doses of fingolimod versus interferon β-1a in patients with relapsing-remitting multiple sclerosis with optional extension phase. NCT00340834.
18. Randomised, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the MRI efficacy and the safety of six months' administration of SB-683699 in subjects with relapsing-remitting multiple sclerosis. NCT00395317.
19. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRImonitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371(9630):2085-2092.
20. Teva Pharmaceutical Industries. A multinational, multicenter, openlabel, single-assignment extension of the MS-LAQ-301 study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis. NCT00988052.
21. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26(9):2067-2074.
22. Wierinckx A, Breve J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol. 2005;166(1-2):132-143.
23. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13(6):604-610.
24. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76(5):950-960.
25. Sanofi-Aventis. Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses. NCT00803049.
26. Sanofi-Aventis. A randomized, multinational, double-blind, placebocontrolled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis. NCT00475865.
27. Sanofi-Aventis. A randomized, multinational, double-blind, placebocontrolled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis. NCT00489489.
28. Sanofi-Aventis. An international, multi-center, randomized, doubleblind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis. NCT00622700.
29. Eli Lilly and Company. An open label follow-on study to assess the ongoing safety of MBP8298 in subjects with secondary progressive multiple sclerosis. NCT00870155.
30. Eli Lilly and Company. A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. NCT00869726.
31. Centocor I. A Phase II, double-blind, placebo-controlled, randomized, dose-ranging study of multiple subcutaneous injections of human monoclonal antibody to IL-12 p40 (CNTO1275) in subjects with relapsing-remitting multiple sclerosis. NCT00207727.
32. EMD Serono. An open-label, multicenter Phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in subjects with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension). NCT00853762.
33. Karnezis T, Mandemakers W, McQualter JL, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci. 2004;7(7):736-744.
34. Liebscher T, Schnell L, Schnell D, et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol. 2005;58(5):706-719.
35. Fontoura P, Ho PP, DeVoss J, et al. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol. 2004;173(11):6981-6992.
36. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8(6):745-751.
37. Lee X, Yang Z, Shao Z, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci. 2007;27(1):220-225.
38. Satoh J, Tabunoki H, Yamamura T, Arima K, Konno H. TROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2007;33(1): 99-107.
39. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65(3):304-315.
40. Rafei M, Campeau PM, Aguilar-Mahecha A, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009;182(10):5994-6002.
41. Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 2003;422(6933):688-694.
42. Hadassah Medical Organization. Explorative trial to investigate the migration ability of mesenchymal bone marrow stem cells (MSC) in the central nervous system (CNS) following their intrathecal administration in severe cases of multiple sclerosis (MS). NCT00781872.
43. The Cleveland Clinic and University Hospital Case Medical Center. A Phase I study to assess the feasibility, safety, and tolerability of autologous mesenchymal stem cell transplantation in patients with relapsing forms of multiple sclerosis. NCT00813969.